BioPharma Dive Mar 23, 2026 Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
BioPharma Dive Mar 6, 2026 Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
BioPharma Dive Feb 4, 2026 Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
BioPharma Dive Jan 12, 2026 JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year